202 related articles for article (PubMed ID: 37240913)
1. Laboratory and Clinical Settings of Heavy/Light Chain (HLC) Assays in the Management of Monoclonal Gammopathies and Multiple Myeloma.
Napodano C; Ioannilli L; Basile V; Gulli F; Carnazzo V; Pignalosa S; Di Biase L; Cavaleri E; Racco C; Equitani F; Marino M; Basile U
J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240913
[TBL] [Abstract][Full Text] [Related]
2. Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports.
Gagliardi A; Carbone C; Russo A; Cuccurullo R; Lucania A; Cioppa PD; Misso G; Caraglia M; Tommasino C; Mastrullo L
Oncol Lett; 2016 Oct; 12(4):2363-2370. PubMed ID: 27698801
[TBL] [Abstract][Full Text] [Related]
3. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
[TBL] [Abstract][Full Text] [Related]
5. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
6. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.
Andrade-Campos M; Murillo-Flórez I; García-Sanz R; Giraldo P
Clin Chem Lab Med; 2017 Aug; 55(10):1598-1604. PubMed ID: 28284031
[TBL] [Abstract][Full Text] [Related]
7. Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies.
Eckold J; Poenisch W; Drogies T; Kratzsch J; Teupser D; Thiery J; Bruegel M
Clin Lab; 2014; 60(9):1491-500. PubMed ID: 25291945
[TBL] [Abstract][Full Text] [Related]
8. Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia.
Ermak N; Nguyen-Khoa T; Alyanakian MA
Ann Biol Clin (Paris); 2016 Oct; 74(5):597-605. PubMed ID: 27707674
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite™) assays for diagnosing and monitoring monoclonal gammopathies.
Kraj M
Adv Clin Exp Med; 2014; 23(1):127-33. PubMed ID: 24596015
[TBL] [Abstract][Full Text] [Related]
10. [The role of the assessment of heavy/light chain pairs of immunoglobulin in monoclonal gammopathies].
Ščudla V; Pika T; Minařík J
Vnitr Lek; 2015 Jan; 61(1):60-1, 63-71. PubMed ID: 25693618
[TBL] [Abstract][Full Text] [Related]
11. Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma.
Chae H; Han E; Yoo J; Lee J; Lee JJ; Cha K; Kim M; Kim Y; Lee SE; Min CK
Clin Chim Acta; 2018 Apr; 479():7-13. PubMed ID: 29324245
[TBL] [Abstract][Full Text] [Related]
12. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
Harutyunyan NM; Vardanyan S; Ghermezi M; Gottlieb J; Berenson A; Andreu-Vieyra C; Berenson JR
Br J Haematol; 2016 Jul; 174(1):81-7. PubMed ID: 27017948
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.
Batinić J; Perić Z; Šegulja D; Last J; Prijić S; Dubravčić K; Volarić L; Sertić D; Radman I; Bašić-Kinda S; Matišić D; Batinić D; Labar B; Nemet D
Croat Med J; 2015 Jun; 56(3):263-71. PubMed ID: 26088851
[TBL] [Abstract][Full Text] [Related]
14. Analytical validation of the Hevylite assays for M-protein quantification.
Jacobs JFM; Haagen IA; Lodder A; van der Kroft C; de Kat Angelino CM; Croockewit S; Nieuwenhuys E; Gelderman KA
Clin Chem Lab Med; 2018 Jun; 56(7):1169-1175. PubMed ID: 29397379
[TBL] [Abstract][Full Text] [Related]
15. The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach.
Ríos-Tamayo R; Puig N; Algarín M; García de Veas Silva JL; Barbosa N; Encinas C; Hernández JÁ; Alonso R; Campos ML; Rodríguez T; Leivas A; Olivares MJ; Sánchez MJ; Paiva B; Lahuerta JJ; Martínez-López J
Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829367
[TBL] [Abstract][Full Text] [Related]
16. Serum free light chains in clinical laboratory diagnostics.
Jenner E
Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
[TBL] [Abstract][Full Text] [Related]
17. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
18. Reference change values of M-protein, free light chain and immunoglobulins in monoclonal gammopathy.
Evliyaoglu O; van Helden J; Jaruschewski S; Imöhl M; Weiskirchen R
Clin Biochem; 2019 Dec; 74():42-46. PubMed ID: 31526775
[TBL] [Abstract][Full Text] [Related]
19. The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response.
Shimizu K; Kamiya Y; Itoh J; Okada J; Lim M; Sugiyama S
Clin Case Rep; 2018 Jan; 6(1):96-102. PubMed ID: 29375846
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
